In a mouse model of postmenopausal heart disease, the administration of MCC950 in mice for 8 weeks three times a week (10 mg/kg) limited hypertrophic remodeling and improved systolic and diastolic function and reduced atrial natriuretic peptide (ANP) and BNP mRNA levels [96]. The gene discussed is NPPA; the disease is heart disorder.